Bhat, Shubha
Limdi, Jimmy K.
Cross, Raymond K.
Farraye, Francis A.
Article History
Accepted: 9 June 2021
First Online: 26 June 2021
Declarations
:
: Shubha Bhat has not conflict of interests to disclose. Jimmy Limdi has received speaker and consultancy fees from AbbVie, Arena pharmaceuticals, Galapagos, Janssen, MSD, Takeda, and Pfizer and research support from Galapagos and Takeda. Raymond K. Cross has participated in consulting and/or advisory boards, for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Samsung Bioepis, and Takeda. Francis A. Farraye has participated in advisory boards for BMS, Braintree labs, Gilead, GI Reviewers, GSK, Janssen, Pfizer, and Sebela. He is a stock owner of Innovation Pharmaceuticals. He sits on a data safety monitoring board for Lilly and Theravance.